Ocular Drug Delivery System: Recent Advances in Treatment of Eye
Keywords:
ocular drug delivery; blood-ocular barriers; in situ gel; nanocarriers; contact lenses; implants; suprachoroidal; gene therapy; glaucoma; retinal diseaseArticle URL
Abstract
The eye is shielded by static and dynamic barriers that hinder drug delivery: typically, less than 5% of the topical dose is absorbed after instillation into the eye, and the posterior segment is nearly impervious to drops. Eye disease, including glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, uveitis, dry eye and infection are leading causes of visual impairment and are on the rise due to older populations and the growing prevalence of diabetes. The last 20 years have seen the transition from the traditional solutions (suspensions and ointments) to systems of prolonged residence time and penetration, such as in situ gels, mucoadhesive polymers, cyclodextrins, nano emulsions, nanoparticles, liposomes, niosomes, dendrimers, inserts, contact lenses, microneedles and implants. Concurrently, retinal disease treatment has evolved with the introduction of biologics, gene therapy, and port-delivery and suprachoroidal techniques. This review provides a summary of anatomy and barriers to the eye, routes of administration, traditional and novel delivery systems, evaluation, marketed products and clinical trends, and remaining regulatory, safety and translational challenges. The purpose is to give a structured information as a general review to formulation scientists and students.
References
REFERENCES
1. World Health Organization. World report on vision. Geneva: WHO; 2019.
2. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-360.
3. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995;16(1):39-43.
4. Loftsson T, Stefánsson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand. 2002;80(2):144-150.
5. Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci. 2009;50(7):3346-3352.
6. Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial (PEACHTREE). Ophthalmology. 2020;127(7):948-955.
7. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47-64
USP<771> Opthalmic product, quality test; USP <785> Osmolality and Osomolarity ; USP <789> Particulate matter in ophthalmic solutions; USP<71> Sterility test ;USP<51> Antimicribial effectiveness testing
8. Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735-754.
9. Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv. 2016;23(8):3017-3026.
10. Russell SR, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849-860.
11. Campochiaro PA, Marcus DM, Awh CC, et al. The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized Phase 2 Ladder clinical trial. Ophthalmology. 2019;126(8):1141-1154.
12. Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011;6(4):317-329
13. Kang-Mieler, J.J.; Dosmar, E.; Liu, W.; Mieler, W.F. Extended ocular drug delivery systems for anterior and posterior segments: Biomaterial options and applications. Expert Opin. Drug Deliv. 2016,14, 611–620.
14. Allyn, M.M.; Luo, R.H.; Hellwarth, E.B.; Swindle-Reilly, K.E. Considerations for Polymers Used in ocular drug Delivery. Front. Med. 2022, 8, 787644
15. Han, H.; Li, S.; Xu, M.; Zhong, Y.; Fan, W.; Xu, J.; Zhou, T.; Ji, J.; Ye, J.; Yao, K. Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives. Adv. Drug Deliv. Rev. 2023, 196, 114770
16. Biswas, A.; Kumar, S.; Choudhury, A.D.; Bisen, A.C.; Sanap, S.N.; Agrawal, S.; Mishra, A.; Verma, S.K.; Kumar, M.; Bhatta, R.S. Polymers and their engineered analogues for ocular drug delivery: Enhancing therapeutic precision. Biopolymers 2024, 115, e23578
17. Manivannan, R.K.; Sharma, N.; Kumar, V.; Jayaraj, I.; Vimal, S.; Umesh, M. A comprehensive review on natural macromolecular biopolymers for biomedical applications: Recent advancements, current challenges, and future outlooks. Carbohydr. Polym. Technol. Appl. 2024, 8, 100536.
18. Kasaai, M.R. Biopolymer-Based Materials for Medicine and Health Care: A Review. J. Biomed.Res. Environ. Sci. 2025, 6, 1737–1755.
19. Nshimiyimana, P.; Major, I.; Colbert, D.M.; Buckley, C. Progress in the biomedical application of biopolymers: An overview of the status quo and outlook in managing intrauterine adhesions. Macromol 2025, 5, 25.
20. Edo, G.I.; Ndudi, W.; Ali, A.M.; Yousif, E.; Jikah, A.N.; Isoje, E.F.; Igbuku, U.A.; Mafe, A.N.; Opiti, R.A.; Madueke, C.J.; et al. Biopolymers: An inclusive review. Hybrid Adv. 2025, 9, 100418
21. Tighe, B.J. A decade of silicone hydrogel development: Surface properties, mechanical properties, and ocular compatibility. Eye Contact Lens 2013, 39, 4–12. [CrossRef] [PubMed]
22. Yoon, S.S.; Carroll, N.M.; Chiocca, E.A.; Tanabe, K.K. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann. Surg. 1998, 228, 366–374.
23. Brandt, C.R.; Kalil, R.E.; Agarwala, S. Replication Competent, a Virulent Herpes Simplex Virus as a Vector for Neural and Ocular Gene Therapy. U.S. Patent US106826, 22 August 2000.
24. Campbell, J.P.; McFarland, T.J.; Stout, J.T. Ocular Gene Therapy. Dev. Ophthalmol. 2016, 55, 317–321. ]
25. Uthra, S.; Kumaramanickavel, G. Gene therapy in ophthalmology. Oman. J. Ophthalmol. 2009, 2, 108–110.
26. Hauswirth, W.; Campichiaro, P.A.; Berns, K.I. Raav Vector Compositions and Methods for the Treatment of Choroidal Neovascularization. NZ Patent NZ535100, 30 April 2008
27. Peppas, N.A.; Bures, P.; Leobandung, W.; Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 2000, 50, 27–46
28. Siepmann, J.; Siepmann, F. Modeling of diffusion controlled drug delivery. J. Control. Release 2012, 161, 351–362.
29. Jager, R.D.; Aiello, L.P.; Patel, S.C.; Cunningham, E.T., Jr. Risks of intravitreous injection: A comprehensive review. Retina 2004, 24, 676–698.
30. Kim, Y.C.; Chiang, B.; Wu, X.; Prausnitz, M.R. Ocular delivery of macromolecules. J. Control. Release 2014, 190, 172–181.
31. Del Amo, E.M.; Urtti, A. Current and future ophthalmic drug delivery systems: A shift to the posterior segment. Drug Discov. Today 2008, 13, 135–143.
32. Yasukawa, T.; Ogura, Y.; Tabata, Y.; Kimura, H.; Wiedemann, P.; Honda, Y. Drug delivery systems for vitreoretinal diseases. Prog.Retin. Eye Res. 2004, 23, 253–281.
33. Ciolino, J.B.; Hoare, T.R.; Iwata, N.G.; Behlau, I.; Dohlman, C.H.; Langer, R.; Kohane, D.S. A drug-eluting contact lens. Investig. Ophthalmol. Vis. Sci. 2009, 50, 3346–3352.
34. Peng, C.-C.; Burke, M.T.; Carbia, B.E.; Plummer, C.; Chauhan, A. Extended drug delivery bycontact lenses for glaucoma therapy.J. Control. Release 2012, 162, 152–158.
35. Maulvi, F.A.; Soni, T.G.; Shah, D.O. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv. 2016, 23, 3017–3026.
36. Kim, J.; Conway, A.; Chauhan, A. Extended delivery of ophthalmic drugs by silicone hydrogel contact lenses. Biomaterials 2008, 29, 2259–2269.
37. White, C.J.; Byrne, M.E. Molecularly imprinted therapeutic contact lenses. Expert Opin. Drug Deliv. 2010, 7, 765–780.
38. Patel, S.R.; Lin, A.S.; Edelhauser, H.F.; Prausnitz, M.R. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res. 2011, 28, 166–176.
39. Lee, J.W.; Park, J.-H.; Prausnitz, M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008, 29, 2113–2124.
40. Jiang, J.; Gill, H.S.; Ghate, D.; McCarey, B.E.; Patel, S.R.; Edelhauser, H.F.; Prausnitz, M.R. Coated microneedles for drug delivery to the eye. Investig. Ophthalmol. Vis. Sci. 2007, 48, 4038–4043.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Tushar Thakur, Govind Sharma

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the Journal of Translational Pharmaceutical Sciences and Technology (JTPST) a non-exclusive license to publish and distribute the article. Published articles are licensed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license. This license permits others to share and adapt the work for non-commercial purposes, provided appropriate credit is given to the original author(s) and source.